Preveon

Adefovir Dipivoxil

A nucleoside analogue antiviral which is effective against viral polymerases (hepadnaviruses, retroviruses—e.g., HIV—herpesviruses—e.g., CMV), and used to treat hepatitis B in adults who have evidence of active viral replication, increased LFTs, histologically active liver disease, and evidence of HBV resistant to other antivirals—e.g., lamivudine.
Benefits 48 weeks of adefovir dipivoxil results in histologic liver improvement, reduces serum HBV DNA and alanine aminotransferase (LFTs), and slows progression of chronic hepatitis B.
Adverse effects Renal toxicity requiring monitoring, asthenia, diarrhoea, dyspepsia, nausea, severe acute exacerbation of hepatitis B after discontinuing.
Mechanism of action Slows progression of chronic hepatitis B by interfering with viral replication and causing DNA chain termination after its incorporation into viral DNA.

Preveon®

Adefovir dipivoxil, see there.
Mentioned in ?
References in periodicals archive ?
Nucleotide analog reverse transcriptase inhibitors such as adefovir (Preveon) and tenofovir (Viread) are very easy to use and have far fewer resistance issues.
Adefovir (Preveon) has not been tested in people but seems to have some in vitro efficacy against smallpox.
Preveon (adefovir dipivoxil) is a new drug from Gilead Sciences.